Furthermore, the estimated effect of SGLT2 inhibition on prostate cancer could at least in part be influenced by different ancestries, disease status, and survival bias, given the relatively late age-at-onset of prostate cancer. Here, SLC5A2 is linked to Familial prostate cancer.